CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab

With CANTOS, Novartis's canakinumab has become the first investigational treatment to show that selectively targeting inflammation significantly reduces cardiovascular risk, albeit modestly, but with the added bonus of reducing lung cancer.